Perfuse Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2040
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Treatment of Glaucoma Using Endothelin Receptor Antagonists (US 11,738,007) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases (US 11,786,510) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Compositions for Treatment of Ocular Diseases (US 11,873,279) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,738,007 | Treatment of Glaucoma Using Endothelin Receptor Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 12,778,933 | Treatment of Glaucoma Using Endothelin Receptor Antagonists In force · Low confidence | In force | Low confidence | |
| US 11,873,279 | Compositions for Treatment of Ocular Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,735,411 | Compositions for Treatment of Ocular Diseases In force · Low confidence | In force | Low confidence | |
| US 11,786,510 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 12,622,894 | Pharmaceutical Compositions and Intravitreal Drug Delivery Systems for the Treatment of Ocular Diseases In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned